Each tablet contains the following inactive ingredients: microcrystalline cellulose, hypromellose, mannitol, tartaric acid, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, ferrosoferric oxide, and iron oxide red.

Rinvoq is a disease-modifying antirheumatic drug (DMARD). It belongs to a class of medications known as Janus kinase (JAK) inhibitors.

AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis.

Rinvoq has an average rating of 6.3 out of 10 from a total of 130 reviews on Drugs.com. 50% of reviewers reported a positive experience, while 29% reported a negative experience.

Following eight weeks of Rinvoq treatment, 23 of 27 (85.2%) patients with ulcerative colitis experienced a clinical response and 22 of 27 (81.5%) experienced clinical remission.

RINVOQ is a prescription medicine used to treat adults with moderate to severe ulcerative colitis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with ulcerative colitis.

Rinvoq is usually taken once per day, with or without food. Swallow the tablet whole and do not crush, chew, or break a tablet. Call your doctor if you see part of the Rinvoq tablet in your stool. You may need frequent medical tests before and while taking Rinvoq.

Generic Name: upadacitinib. Upadacitinib is used to treat certain types of arthritis (such as psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis). It helps decrease pain, tenderness, and swelling in the joints. Upadacitinib is also used to treat a skin condition called atopic dermatitis.

Some people may feel the effects of Rinvoq after one week, but most people who respond will have significant improvement by 12 weeks. The improvements in pain, swelling and stiffness of rheumatoid arthritis have lasted over one year in many people.

Rinvoq has a boxed warning about cancer. A boxed warning is a serious warning from the FDA. People taking Rinvoq may have an increased risk for certain types of cancer. These types of cancer include lymphoma and non-melanoma skin cancer.

The cost for Rinvoq oral tablet, extended release 15 mg is around $6,459 for a supply of 30 tablets, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans.

Common Rinvoq side effects may include:

• flu symptoms;
• nausea;
• acne, rash, headache;
• stomach pain;
• weight gain;
• muscle pain;
• folliculitis (redness or crusting around your hair follicles);
• cold symptoms such as stuffy nose, sneezing, sore throat;

You may pay as little as $5 a month* for RINVOQ with the RINVOQ Complete Savings Card. The RINVOQ Complete Savings Card enables eligible, commercially insured patients to pay as little as $5 a month for their RINVOQ prescription. *Not available to all U.S patients. Restrictions apply.